Profile data is unavailable for this security.
About the company
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
- Revenue in SEK (TTM)386.40m
- Net income in SEK-201.10m
- Incorporated1994
- Employees72.00
- LocationOrexo ABP.O. Box 303UPPSALA 751 05SwedenSWE
- Phone+46 187808800
- Fax+46 187808888
- Websitehttps://orexo.se/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Enzymatica AB (publ) | 52.73m | -54.14m | 472.12m | 21.00 | -- | 3.48 | -- | 8.95 | -0.2257 | -0.2257 | 0.2198 | 0.559 | 0.292 | 1.26 | 4.54 | 2,510,953.00 | -29.98 | -29.10 | -31.26 | -34.48 | 63.76 | 63.82 | -102.68 | -73.32 | -- | -- | 0.0095 | -- | -10.47 | -5.76 | -6.94 | -- | -14.62 | -- |
| Navamedic ASA | 537.58m | -22.38m | 478.87m | 45.00 | -- | 1.51 | 64.42 | 0.8908 | -1.11 | -1.11 | 26.97 | 13.93 | 0.9351 | 3.48 | 8.28 | -- | -3.89 | -0.5784 | -5.27 | -0.8691 | 38.97 | 39.81 | -4.16 | -0.5578 | 0.887 | 0.4484 | 0.384 | -- | 6.38 | 21.92 | -329.13 | -- | -- | -- |
| Dicot Pharma AB | 126.00k | -84.00m | 612.85m | 4.00 | -- | 6.79 | -- | 4,863.89 | -0.0459 | -0.0459 | 0.00007 | 0.0449 | 0.001 | 10.68 | 0.0371 | 42,000.00 | -69.50 | -94.78 | -75.43 | -111.46 | -61,341.27 | -32,616.05 | -66,663.49 | -37,576.05 | 8.82 | -- | 0.00 | -- | -88.60 | -47.16 | -30.66 | -- | -- | -- |
| Infant Bacterial Therapeutics AB | 0.00 | -65.17m | 729.02m | 10.00 | -- | 7.16 | -- | -- | -4.84 | -4.84 | 0.00 | 7.82 | 0.00 | -- | -- | -- | -32.48 | -26.32 | -47.29 | -29.53 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 52.40 | -- | -- | -- |
| Cinclus Pharma Holding publ AB | 57.47m | -183.97m | 816.27m | 21.00 | -- | 2.25 | -- | 14.20 | -3.95 | -3.95 | 1.23 | 7.79 | 0.1002 | -- | 5.00 | 2,736,714.00 | -32.06 | -63.39 | -38.12 | -84.13 | -- | -- | -320.11 | -1,135.74 | -- | -- | 0.0209 | -- | 1,154.80 | -- | -9.49 | -- | -- | -- |
| Vistin Pharma ASA | 430.07m | 71.08m | 898.14m | 77.00 | 12.64 | 2.87 | 9.71 | 2.09 | 1.69 | 1.69 | 10.20 | 7.42 | 1.10 | 1.91 | 6.75 | -- | 18.14 | 10.64 | 21.94 | 13.02 | 66.50 | 62.12 | 16.53 | 10.81 | 1.54 | -- | -- | -- | 5.41 | 12.31 | 19.13 | -- | -20.67 | 24.57 |
| Orexo AB | 386.40m | -201.10m | 933.72m | 72.00 | -- | 1.89 | -- | 2.42 | -5.80 | 18.42 | 11.15 | 14.22 | 0.4073 | 1.29 | 2.02 | 5,366,667.00 | -21.20 | -28.03 | -29.75 | -42.57 | 89.96 | 83.88 | -52.04 | -74.89 | 3.70 | -3.00 | 0.5005 | -- | -12.46 | -47.69 | 15.63 | -- | -- | -- |
| SynAct Pharma AB | 0.00 | -106.27m | 1.06bn | 8.00 | -- | 5.42 | -- | -- | -2.20 | -2.20 | 0.00 | 3.65 | 0.00 | -- | -- | 0.00 | -45.16 | -85.38 | -50.22 | -99.19 | -- | -- | -- | -- | -- | -63.96 | 0.0071 | -- | -- | -- | 61.82 | -- | -- | -- |
| Arcticzymes Technologies ASA | 107.08m | 9.83m | 1.11bn | 55.00 | 113.38 | 3.44 | 59.74 | 10.34 | 0.2011 | 0.2011 | 2.17 | 6.63 | 0.3187 | 0.2928 | 1.80 | -- | 2.93 | 7.41 | 3.08 | 7.94 | 95.84 | 95.73 | 9.18 | 19.47 | 15.53 | -- | 0.0155 | -- | 7.92 | 3.80 | 16.66 | -33.11 | 13.75 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Handelsbanken Fonder ABas of 31 May 2025 | 206.25k | 0.59% |
| SEB Funds ABas of 30 Jan 2026 | 172.88k | 0.50% |
| Skandia Investment Management ABas of 28 Nov 2025 | 147.38k | 0.43% |
| Storebrand Asset Management ASas of 30 Nov 2025 | 137.48k | 0.40% |
| Consultinvest Asset Management SGR SpAas of 30 Dec 2025 | 79.70k | 0.23% |
| Lannebo Kapitalf�rvaltning AB (Sweden)as of 30 Nov 2025 | 39.40k | 0.11% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 17.34k | 0.05% |
| Bessemer Investment Management LLCas of 31 Oct 2025 | 14.06k | 0.04% |
| Victory Capital Management, Inc. (Investment Management)as of 31 Dec 2025 | 7.33k | 0.02% |
| Voya Investments LLCas of 31 Dec 2025 | 5.99k | 0.02% |
